Beijing Beier Bioengineering Co., Ltd.

Established in Beijing in September 1995, Beijing Beier Bioengineering Co., Ltd. is a high-tech enterprise specializing in the production of in vitro diagnostic reagents. The quality system has passed the national drug GMP certification and ISO13485 certification. Since its establishment, Beier Bio has been focusing on the field of in vitro diagnostics (IVD). It is a high-tech enterprise specializing in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments. The company adheres to scientific and technological innovation as the guidance, and has formed a common development of various detection platforms such as enzyme-linked immunoassay diagnostic reagent platform, colloidal gold rapid diagnostic reagent platform, chemiluminescence diagnostic reagent platform, biochemical diagnostic reagent platform, molecular diagnostic reagent platform and other detection platforms. It has become one of the enterprises with the most abundant in vitro diagnostic products in China. Beier Bio has independently developed and mass-produced a full-automatic chemiluminescence immunoassay analyzer for the detection of supporting chemiluminescence reagents. As a representative of domestic chemiluminescence immunoassay analyzers, the company′s products are stable, reliable, highly intelligent, and fully automated. All technical parameters have reached the international advanced level. The company has undertaken a number of major industrial and scientific research projects at the national and municipal levels, and has multiple new drug certificates and dozens of invention patents.

Since the establishment of the company in 1995, the company has relied on strong scientific research strength and excellent professional personnel to forge ahead in the field of infectious diseases, and has taken the lead in launching TORCH series, EB series, hand-foot-mouth disease series, respiratory pathogen series, hepatitis D, Hepatitis G series and viral myocarditis series and many other products. The company has obtained product approval for more than 200 products that have been mass-produced. The sales network covers thousands of hospitals′ clinical laboratory, pediatrics, gynecology, cardiology, neurology, respiratory and other departments across the country.

In 2017, Beier Bio wholly acquired Beijing SAVI Biotechnology Co., Ltd. SAVI Bio focuses on the R&D, production and professional services in the field of automatic magnetic particle chemiluminescence immunoassay system diagnosis. Relying on the strong manufacturing strength of AVIC Group, it has reached the domestic leading level in equipment manufacturing and reagent R&D and production. The company′s products cover a full range of automatic chemiluminescence immunoassay analyzers, magnetic particle chemiluminescence immunodiagnostic reagents, master all core technologies, and possess a number of invention patents for fully automatic chemiluminescence analyzers.

Beier Bio takes human health as its mission and focuses on exploring new areas of detection. After more than 20 years of accumulation, the company has formed a complete product line of infectious diseases, eugenics, respiratory, EB virus, hand, foot and mouth, hepatitis, tumors, liver fibrosis, hypertension, diabetes, thyroid function, reproductive endocrine, and autoantibody. Together with the domestically-made full-automatic chemiluminescence analyzer and colloidal gold immunoassay analyzer with independent intellectual property rights, the company has the ability to provide a one-stop comprehensive testing solution for clinical laboratories.